Current staging and prognostic factors in melanoma

Area of Science:

• Oncology
• Dermatology
• Cancer Staging

Background:

• The American Joint Commission for Cancer (AJCC) staging system is crucial for melanoma patient management.
• Current AJCC staging relies on primary tumor characteristics, nodal status, and distant metastasis.
• Prognostic factors for early-stage melanoma may differ from those influencing sentinel lymph node positivity and overall survival.

Purpose of the Study:

• To review the factors utilized in the current AJCC Cancer Staging system for melanoma.
• To examine the prognostic indicators for different stages of melanoma (I-IV).
• To investigate the relationship between factors predicting sentinel lymph node positivity and those predicting patient survival.

Main Methods:

• Review of the established criteria within the American Joint Commission for Cancer staging manual for melanoma.
• Analysis of primary tumor factors (thickness, ulceration, mitotic index) for Stage I/II.
• Evaluation of nodal factors (metastases number/size, satellitosis, in-transit disease) for Stage III and distant disease/LDH for Stage IV.

Main Results:

• Stage I/II melanoma staging incorporates tumor thickness, ulceration, and mitotic index.
• Stage III melanoma classification depends on nodal involvement characteristics and tumor ulceration.
• Stage IV melanoma prognosis is stratified by distant metastasis and lactate dehydrogenase levels.

Conclusions:

• The AJCC staging system comprehensively categorizes melanoma patients based on disease extent and tumor biology.
• While sentinel lymph node positivity is a key factor, its predictors may not perfectly correlate with long-term survival.
• Further research may be needed to refine prognostic models, especially for T1 melanomas.